Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq:
CNTX), a biopharmaceutical company advancing medicines for solid
tumors, today announced the appointment of Claudio Dansky
Ullmann, M.D. as Chief Medical Officer (“CMO”) and Karen
Andreas, M.S. as Vice President, Clinical Operations.
“We are thrilled to welcome Dr. Dansky Ullmann and Ms. Andreas
to our team at this exciting time as the Company advances its
product candidates, CTIM-76 and CT-95, into Phase 1 clinical
trials,” said Martin Lehr, CEO of Context. “Dr. Dansky Ullmann
and Ms. Andreas are industry veterans with deep expertise in
oncology and T cell therapies, and a proven track record of
advancing programs through clinical development.”
Dr. Dansky Ullmann brings over 30 years of experience in early
and late-stage oncology therapeutics development. Most recently, he
was the CMO at Avenge Bio, where Dr. Dansky Ullmann guided the
clinical advancement of AVB-001 allogeneic cell therapy for ovarian
cancer. Prior to Avenge, Dr. Dansky Ullmann was CMO at MaxCyte
where he was responsible for the development of the CARMA™ chimeric
antigen receptor (CAR) therapy program, including MCY-M11, a
mesothelin-targeting CAR therapy. Previously, he was the Senior
Vice President, Head of Clinical Development at Infinity
Pharmaceuticals, where he led the development of Copiktra® through
FDA approval and eganelisib through first in human studies.
Earlier, he was Global Clinical Lead in the Oncology Therapy Area
Unit at Takeda Pharmaceuticals. Before, Dr. Dansky Ullmann was a
Senior Investigator in the Cancer Therapy Evaluation Program at the
National Cancer Institute, where he was involved in the strategic
development of novel agents through Phase 1-3 clinical trials. Dr.
Dansky Ullmann earned his M.D. at the School of Medicine,
Universidad de Buenos Aires and completed his medical oncology
training at Guemes Private Hospital, Buenos Aires.
“I am excited to join the leadership team at Context, which is
focused on building an innovative portfolio of clinical stage T
cell engaging bispecific therapeutics,” said Dr. Dansky Ullmann. “I
look forward to contributing to the team to help bring potential
best-in-class and first-in-class treatments to patients in
need.”
Ms. Andreas’ biopharma career spans almost 20 years in multiple
cross-functional roles across the drug development process,
maintaining a primary focus in oncology at small to midsize
companies. Prior to joining Context, Ms. Andreas was Vice
President, Clinical Operations at Avenge Bio where she was
responsible for oversight of all clinical trial activities,
clinical operations strategy, planning, and execution for a first
in human allogeneic cell therapy for ovarian cancer. Previously, at
Boston Pharmaceuticals, Ms. Andreas led clinical operations and
program management for zeteletinib through proof of concept and
other oncology assets through early development. Ms. Andreas
also spent 10 years with Merrimack Pharmaceuticals in various roles
advancing multiple oncology and immunology-focused assets and three
years at ArQule advancing the company's first early-stage studies.
Ms. Andreas holds a bachelor’s degree in biology from Colby College
and a Master of Science from Tufts University School of
Medicine.
Ms. Andreas stated, “I look forward to working with the entire
Context team and utilizing my clinical operations background to
support the advancement of the Company’s two clinical stage assets,
CTIM-76 and CT-95.”
Inducement Grant Under Nasdaq Listing Rule
5635(c)(4) In connection with the employment of Dr.
Dansky Ullmann, the Company will grant a non-qualified stock option
award in an amount of 202,170 shares of the Company's common stock
as an inducement material to him accepting employment with the
Company. Such stock option will have an exercise price equal
to the closing price of the Company’s common stock as reported by
Nasdaq as of the close of market on August 1, 2024, which will be
the date of grant.
The Company also hired an additional employee on August 1, 2024
and anticipates two additional hires starting on August 12, 2024.
These employees will be granted non-qualified stock option awards
in an aggregate amount of 115,237 shares of the Company's common
stock as an inducement material to each of them accepting
employment with the Company, with an exercise price equal to the
closing price of the Company’s common stock as reported on Nasdaq
as of the close of market on the date of commencement of such
employee’s employment.
All such stock options will vest as to 25% of the shares on the
first anniversary of the date of grant and in successive equal
monthly installments over the subsequent three years, subject to
continued employment with the Company and the terms and conditions
in the stock option agreement. All such stock options are
respectively granted as an inducement award pursuant to Rule
5635(c)(4) of the Nasdaq Listing Rules.
About Context Therapeutics®Context Therapeutics
Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing
medicines for solid tumors that is building an innovative portfolio
of clinical-stage T cell engaging bispecific therapeutics. Product
candidates include CTIM-76, a Claudin 6 x CD3 bispecific antibody,
and CT-95, a mesothelin x CD3 bispecific antibody. Context is
headquartered in Philadelphia. For more information, please
visit www.contexttherapeutics.com or follow the Company
on X (formerly Twitter) and LinkedIn.
Forward-looking StatementsThis press release
contains “forward-looking statements” that involve substantial
risks and uncertainties for purposes of the safe harbor provided by
the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, included in
this press release regarding strategy, future operations,
prospects, plans and objectives of management, including words such
as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,”
“intend,” and similar expressions (as well as other words or
expressions referencing future events, conditions, or
circumstances) are forward-looking statements. These include,
without limitation, statements regarding (i) the ability of the new
appointments to support the Company and the advancement of its
product candidates; (ii) the potential benefits, characteristics,
safety and side effect profile of our product candidates, (iii) the
ability of our product candidates to have benefits,
characteristics, manufacturability, and a side effect profile that
is differentiated and/or better than third party product
candidates, (iv) the likelihood data will support future
development of our product candidates, and (v) the likelihood of
obtaining regulatory approval for our product candidates.
Forward-looking statements in this release involve substantial
risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by the forward-looking
statements, and we therefore cannot assure you that our plans,
intentions, expectations, or strategies will be attained or
achieved. Other factors that may cause actual results to differ
from those expressed or implied in the forward-looking statements
in this press release are discussed in our filings with
the U.S. Securities and Exchange Commission, including the
section titled “Risk Factors” contained therein. Except as
otherwise required by law, we disclaim any intention or obligation
to update or revise any forward-looking statements, which speak
only as of the date they were made, whether as a result of new
information, future events, or circumstances or otherwise.
Investor Relations Contact:Jennifer
Minai-AzaryContext TherapeuticsIR@contexttherapeutics.com
Context Therapeutics (NASDAQ:CNTX)
過去 株価チャート
から 11 2024 まで 12 2024
Context Therapeutics (NASDAQ:CNTX)
過去 株価チャート
から 12 2023 まで 12 2024